Elicio (ELTX) Director Julian Adams Receives 21,750-Share Award

What Happened

• Julian Adams, a director of Elicio Therapeutics (ELTX), received a granted derivative award on 2026-08-31 equal to 21,750 shares. The Form 4 records the acquisition price as $0.00 (no cash paid reported). The award is described in the filing as a stock option that will vest in full by the earlier of August 31, 2027 or the 2027 annual meeting, subject to continued service.

Key Details

• Transaction: Grant (code A) of 21,750 shares (derivative) on 2026-08-31; reported price $0.00.
• Vesting: Vests in full on the earlier of August 31, 2027 or the Issuer’s 2027 annual meeting, contingent on continued service (footnote).
• Post-transaction holdings: Not included in the provided excerpt of the filing.
• Filing: Form 4 filed 2026-09-02 (Accession 0001230486-26-000002); timing appears in line with Form 4 rules.
• Footnote note: This award represents the annual non-employee director equity award; no additional equity award will be made to Mr. Adams in connection with the 2026 annual meeting.

Context

• This is a routine director equity award (derivative grant) and not an open-market buy or sale. Such awards are typically part of standard compensation for non-employee directors and vest over time; they do not necessarily indicate an immediate cash value or a buy/sell signal for investors.